Global Cancer Therapeutics Market

Cancer Therapeutics Comprehensive Study by Application (Blood cancer, Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Other), Drug Selling (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Other) Players and Region - Global Market Outlook to 2028

Cancer Therapeutics Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 10.9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Cancer Therapeutics Market Scope
Cancer therapeutics has an ever-increasing paradigm and array of tools, shift away from the traditional cytotoxic drugs towards the targeting of proteins intimately involved in driving the cancer phenotype. Huge investment in research and development activities and favorable government regulations for cancer therapeutics has enhanced the development of drugs. These aspects are the major drivers which are stimulating the growth of the very market.

According to AMA, the Global Cancer Therapeutics market is expected to see growth rate of 10.9%

Cancer Therapeutics market companies operating in these industries are focusing more on efficient growth, improvement of operational efficiency and productivity, achieving high safety standards, and focusing on maintaining sustainable development. The market is highly competitive with a few players occupying the major share. The key players are highly focused on developing and innovating new strategies to maintain their market position and customer base. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launches, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Cancer Therapeutics market throughout the predicted period.

Merck & Co. Inc. (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), AbbVie Inc. (United States), Astellas Pharma Inc. (Japan), CTX CRC LTD (Australia), Bristol Myers Squibb Company (United States), Celgene Corporation (United States), Eli Lilly and Company (United States), F. Hoffmann-La Roche Ltd. (Switzerland) and Johnson & Johnson (United States) are some of the key players that are part of study coverage.

Segmentation Overview
The study have segmented the market of Global Cancer Therapeutics market , by Application (Blood cancer, Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer and Other) and Region with country level break-up.

On the basis of geography, the market of Cancer Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Increasing Investment in Research & Development and Top Players are Focusing on Product Enhancement

Market Growth Drivers:
Increasing Incidences of Lung Cancer Due to Rising Smoking Population and Rise in Cancer Awareness & Availability of Oncology Drugs

Challenges:
Adverse Effects Associated with Cancer Drug Therapy

Restraints:
High Cost of Drug Development and the Threat of Failure

Opportunities:
High potential associated with personalized medicines and Increase in purchasing power of developing countries

Market Leaders and their Expansionary Development Strategies
In April 2020, Merck Announced the US Launched of ONTRUZANT, a Biosimilar of Herceptin. ONTRUZENT is indicated for adjuvant treatment of HER2 overexpressing node-positive or node-negative breast cancer as part of a treatment regimen consisting of doxorubicin. ONTRUZANT is being launched in the U.S. by Merck as part of a development and commercialization agreement with Samsung Bioepis.
In January 2019, AbbVie, a research-based global biopharmaceutical company, and Tizona Therapeutics, Inc., a privately held immunotherapy company, announced that they have entered into a global, strategic collaboration to develop and commercialize CD39-targeted therapeutics, including TTX-030, a first-in-class antibody for the treatment of cancer


Key Target Audience
Cancer Drug Manufacturers, Drug Distributor/Suppliers, Research Organizations, Government Regulatory Body and Other

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Report Objectives / Segmentation Covered

By Application
  • Blood cancer
  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Prostate cancer
  • Other
By Drug Selling
  • Revlimid
  • Avastin
  • Herceptin
  • Rituxan
  • Opdivo
  • Gleevec
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidences of Lung Cancer Due to Rising Smoking Population
      • 3.2.2. Rise in Cancer Awareness & Availability of Oncology Drugs
    • 3.3. Market Challenges
      • 3.3.1. Adverse Effects Associated with Cancer Drug Therapy
    • 3.4. Market Trends
      • 3.4.1. Increasing Investment in Research & Development
      • 3.4.2. Top Players are Focusing on Product Enhancement
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Therapeutics, by Application, Drug Selling and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cancer Therapeutics (Value)
      • 5.2.1. Global Cancer Therapeutics by: Application (Value)
        • 5.2.1.1. Blood cancer
        • 5.2.1.2. Breast cancer
        • 5.2.1.3. Lung cancer
        • 5.2.1.4. Colorectal cancer
        • 5.2.1.5. Prostate cancer
        • 5.2.1.6. Other
      • 5.2.2. Global Cancer Therapeutics by: Drug Selling (Value)
        • 5.2.2.1. Revlimid
        • 5.2.2.2. Avastin
        • 5.2.2.3. Herceptin
        • 5.2.2.4. Rituxan
        • 5.2.2.5. Opdivo
        • 5.2.2.6. Gleevec
        • 5.2.2.7. Other
      • 5.2.3. Global Cancer Therapeutics Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Cancer Therapeutics (Price)
  • 6. Cancer Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co. Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AbbVie Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Astellas Pharma Inc. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CTX CRC LTD (Australia)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol Myers Squibb Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Celgene Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Johnson & Johnson (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Cancer Therapeutics Sale, by Application, Drug Selling and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cancer Therapeutics (Value)
      • 7.2.1. Global Cancer Therapeutics by: Application (Value)
        • 7.2.1.1. Blood cancer
        • 7.2.1.2. Breast cancer
        • 7.2.1.3. Lung cancer
        • 7.2.1.4. Colorectal cancer
        • 7.2.1.5. Prostate cancer
        • 7.2.1.6. Other
      • 7.2.2. Global Cancer Therapeutics by: Drug Selling (Value)
        • 7.2.2.1. Revlimid
        • 7.2.2.2. Avastin
        • 7.2.2.3. Herceptin
        • 7.2.2.4. Rituxan
        • 7.2.2.5. Opdivo
        • 7.2.2.6. Gleevec
        • 7.2.2.7. Other
      • 7.2.3. Global Cancer Therapeutics Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Cancer Therapeutics (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Therapeutics: by Application(USD Billion)
  • Table 2. Cancer Therapeutics Blood cancer , by Region USD Billion (2017-2022)
  • Table 3. Cancer Therapeutics Breast cancer , by Region USD Billion (2017-2022)
  • Table 4. Cancer Therapeutics Lung cancer , by Region USD Billion (2017-2022)
  • Table 5. Cancer Therapeutics Colorectal cancer , by Region USD Billion (2017-2022)
  • Table 6. Cancer Therapeutics Prostate cancer , by Region USD Billion (2017-2022)
  • Table 7. Cancer Therapeutics Other , by Region USD Billion (2017-2022)
  • Table 8. Cancer Therapeutics: by Drug Selling(USD Billion)
  • Table 9. Cancer Therapeutics Revlimid , by Region USD Billion (2017-2022)
  • Table 10. Cancer Therapeutics Avastin , by Region USD Billion (2017-2022)
  • Table 11. Cancer Therapeutics Herceptin , by Region USD Billion (2017-2022)
  • Table 12. Cancer Therapeutics Rituxan , by Region USD Billion (2017-2022)
  • Table 13. Cancer Therapeutics Opdivo , by Region USD Billion (2017-2022)
  • Table 14. Cancer Therapeutics Gleevec , by Region USD Billion (2017-2022)
  • Table 15. Cancer Therapeutics Other , by Region USD Billion (2017-2022)
  • Table 16. South America Cancer Therapeutics, by Country USD Billion (2017-2022)
  • Table 17. South America Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 18. South America Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 19. Brazil Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 20. Brazil Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 21. Argentina Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 22. Argentina Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 23. Rest of South America Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 24. Rest of South America Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 25. Asia Pacific Cancer Therapeutics, by Country USD Billion (2017-2022)
  • Table 26. Asia Pacific Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 27. Asia Pacific Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 28. China Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 29. China Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 30. Japan Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 31. Japan Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 32. India Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 33. India Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 34. South Korea Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 35. South Korea Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 36. Taiwan Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 37. Taiwan Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 38. Australia Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 39. Australia Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 40. Rest of Asia-Pacific Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 41. Rest of Asia-Pacific Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 42. Europe Cancer Therapeutics, by Country USD Billion (2017-2022)
  • Table 43. Europe Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 44. Europe Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 45. Germany Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 46. Germany Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 47. France Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 48. France Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 49. Italy Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 50. Italy Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 51. United Kingdom Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 52. United Kingdom Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 53. Netherlands Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 54. Netherlands Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 55. Rest of Europe Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 56. Rest of Europe Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 57. MEA Cancer Therapeutics, by Country USD Billion (2017-2022)
  • Table 58. MEA Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 59. MEA Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 60. Middle East Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 61. Middle East Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 62. Africa Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 63. Africa Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 64. North America Cancer Therapeutics, by Country USD Billion (2017-2022)
  • Table 65. North America Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 66. North America Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 67. United States Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 68. United States Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 69. Canada Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 70. Canada Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 71. Mexico Cancer Therapeutics, by Application USD Billion (2017-2022)
  • Table 72. Mexico Cancer Therapeutics, by Drug Selling USD Billion (2017-2022)
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Company Basic Information, Sales Area and Its Competitors
  • Table 81. Company Basic Information, Sales Area and Its Competitors
  • Table 82. Company Basic Information, Sales Area and Its Competitors
  • Table 83. Company Basic Information, Sales Area and Its Competitors
  • Table 84. Cancer Therapeutics: by Application(USD Billion)
  • Table 85. Cancer Therapeutics Blood cancer , by Region USD Billion (2023-2028)
  • Table 86. Cancer Therapeutics Breast cancer , by Region USD Billion (2023-2028)
  • Table 87. Cancer Therapeutics Lung cancer , by Region USD Billion (2023-2028)
  • Table 88. Cancer Therapeutics Colorectal cancer , by Region USD Billion (2023-2028)
  • Table 89. Cancer Therapeutics Prostate cancer , by Region USD Billion (2023-2028)
  • Table 90. Cancer Therapeutics Other , by Region USD Billion (2023-2028)
  • Table 91. Cancer Therapeutics: by Drug Selling(USD Billion)
  • Table 92. Cancer Therapeutics Revlimid , by Region USD Billion (2023-2028)
  • Table 93. Cancer Therapeutics Avastin , by Region USD Billion (2023-2028)
  • Table 94. Cancer Therapeutics Herceptin , by Region USD Billion (2023-2028)
  • Table 95. Cancer Therapeutics Rituxan , by Region USD Billion (2023-2028)
  • Table 96. Cancer Therapeutics Opdivo , by Region USD Billion (2023-2028)
  • Table 97. Cancer Therapeutics Gleevec , by Region USD Billion (2023-2028)
  • Table 98. Cancer Therapeutics Other , by Region USD Billion (2023-2028)
  • Table 99. South America Cancer Therapeutics, by Country USD Billion (2023-2028)
  • Table 100. South America Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 101. South America Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 102. Brazil Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 103. Brazil Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 104. Argentina Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 105. Argentina Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 106. Rest of South America Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 107. Rest of South America Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 108. Asia Pacific Cancer Therapeutics, by Country USD Billion (2023-2028)
  • Table 109. Asia Pacific Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 110. Asia Pacific Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 111. China Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 112. China Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 113. Japan Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 114. Japan Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 115. India Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 116. India Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 117. South Korea Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 118. South Korea Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 119. Taiwan Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 120. Taiwan Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 121. Australia Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 122. Australia Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 123. Rest of Asia-Pacific Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 124. Rest of Asia-Pacific Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 125. Europe Cancer Therapeutics, by Country USD Billion (2023-2028)
  • Table 126. Europe Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 127. Europe Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 128. Germany Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 129. Germany Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 130. France Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 131. France Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 132. Italy Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 133. Italy Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 134. United Kingdom Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 135. United Kingdom Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 136. Netherlands Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 137. Netherlands Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 138. Rest of Europe Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 139. Rest of Europe Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 140. MEA Cancer Therapeutics, by Country USD Billion (2023-2028)
  • Table 141. MEA Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 142. MEA Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 143. Middle East Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 144. Middle East Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 145. Africa Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 146. Africa Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 147. North America Cancer Therapeutics, by Country USD Billion (2023-2028)
  • Table 148. North America Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 149. North America Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 150. United States Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 151. United States Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 152. Canada Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 153. Canada Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 154. Mexico Cancer Therapeutics, by Application USD Billion (2023-2028)
  • Table 155. Mexico Cancer Therapeutics, by Drug Selling USD Billion (2023-2028)
  • Table 156. Research Programs/Design for This Report
  • Table 157. Key Data Information from Secondary Sources
  • Table 158. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Therapeutics: by Application USD Billion (2017-2022)
  • Figure 5. Global Cancer Therapeutics: by Drug Selling USD Billion (2017-2022)
  • Figure 6. South America Cancer Therapeutics Share (%), by Country
  • Figure 7. Asia Pacific Cancer Therapeutics Share (%), by Country
  • Figure 8. Europe Cancer Therapeutics Share (%), by Country
  • Figure 9. MEA Cancer Therapeutics Share (%), by Country
  • Figure 10. North America Cancer Therapeutics Share (%), by Country
  • Figure 11. Global Cancer Therapeutics share by Players 2022 (%)
  • Figure 12. Global Cancer Therapeutics share by Players (Top 3) 2022(%)
  • Figure 13. Global Cancer Therapeutics share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Merck & Co. Inc. (United States) Revenue: by Geography 2022
  • Figure 17. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 19. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 21. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. AbbVie Inc. (United States) Revenue: by Geography 2022
  • Figure 23. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Astellas Pharma Inc. (Japan) Revenue: by Geography 2022
  • Figure 25. CTX CRC LTD (Australia) Revenue, Net Income and Gross profit
  • Figure 26. CTX CRC LTD (Australia) Revenue: by Geography 2022
  • Figure 27. Bristol Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 28. Bristol Myers Squibb Company (United States) Revenue: by Geography 2022
  • Figure 29. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Celgene Corporation (United States) Revenue: by Geography 2022
  • Figure 31. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 33. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2022
  • Figure 35. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 36. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 37. Global Cancer Therapeutics: by Application USD Billion (2023-2028)
  • Figure 38. Global Cancer Therapeutics: by Drug Selling USD Billion (2023-2028)
  • Figure 39. South America Cancer Therapeutics Share (%), by Country
  • Figure 40. Asia Pacific Cancer Therapeutics Share (%), by Country
  • Figure 41. Europe Cancer Therapeutics Share (%), by Country
  • Figure 42. MEA Cancer Therapeutics Share (%), by Country
  • Figure 43. North America Cancer Therapeutics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Merck & Co. Inc. (United States)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • AbbVie Inc. (United States)
  • Astellas Pharma Inc. (Japan)
  • CTX CRC LTD (Australia)
  • Bristol Myers Squibb Company (United States)
  • Celgene Corporation (United States)
  • Eli Lilly and Company (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Johnson & Johnson (United States)
Select User Access Type

Key Highlights of Report


May 2023 208 Pages 79 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Therapeutics Market Quantitative research analysis
Global Cancer Therapeutics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Cancer Therapeutics study can be customized to meet your requirements. The market size breakdown by type, by end-use application.
The Cancer Therapeutics Market is gaining popularity and expected to see strong valuation by 2028 and may reach USD 179.8 Billion .
According to AMA, the Global Cancer Therapeutics market is expected to see growth rate of xx%.
The Cancer Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Cancer Therapeutics Market Report?

Have a Query? Click Here

Other Related Reports

Gaucher Disease Treatment Comprehensive Study by Therapy (Enzyme Replacement Therapy (Imiglucerase (Cerezyme), Velaglucerase alfa (VPRIV),Taliglucerase alfa (Elelyso), Others, Substrate Replacement T...
$ 3750
Post-Traumatic Stress Disorder Therapeutics Comprehensive Study by End-Users (Male, Female, Children), Drug Class (Antidepressants, Anti-anxiety Drugs, Other Drug Class) Players and Region - Global M...
$ 3500
Thalassemia Comprehensive Study by Type (Alpha-Thalassemia, Beta Thalassemia), Application (Hospital, Clinic, Research Institute, Laboratories), Treatment Type (Blood Transfusions, Iron Chelation The...
$ 3650
Melanoma Therapeutics Comprehensive Study by Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generics), Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, Radiat...
$ 3750
Appendix Cancer Treatment Comprehensive Study by Type (Neuroendocrine Tumors, Carcinomas, Mucinous Adenocarcinoma (low grade, high grade), Global Cell Carcinoids, Intestinal Type Adenocarcinoma, Sign...
$ 3750
Diabetes Therapeutics and Diagnostics Comprehensive Study by Type (Injectable (Insulin, Amylinomimetic), Oral (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Dipeptidyl ...
$ 3750